DELIVER: Extending the benefits of SGLT-2 inhibitors.
Journal
Global cardiology science & practice
ISSN: 2305-7823
Titre abrégé: Glob Cardiol Sci Pract
Pays: Qatar
ID NLM: 101613130
Informations de publication
Date de publication:
01 Aug 2023
01 Aug 2023
Historique:
received:
01
05
2023
accepted:
15
05
2023
medline:
14
8
2023
pubmed:
14
8
2023
entrez:
14
8
2023
Statut:
epublish
Résumé
The DELIVER trial investigated the efficacy and safety of dapagliflozin in patients with heart failure and preserved or mildly reduced ejection fraction. The trial demonstrated that dapagliflozin significantly reduced the risk of worsening heart failure or cardiovascular death compared to placebo. The benefit was mainly driven by a decrease in heart failure hospitalizations, with no significant impact on mortality. Patients with different ejection fractions and diabetes status showed similar treatment effects. Dapagliflozin also improved functional capacity and quality of life. These findings support the use of SGLT-2 inhibitors in HFpEF and HFmrEF, potentially influencing clinical practice and future guidelines.
Identifiants
pubmed: 37575288
doi: 10.21542/gcsp.2023.21
pii: gcsp.2023.21
pmc: PMC10422874
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e202321Informations de copyright
Copyright ©2023 The Author(s).
Références
Circulation. 2021 Jan 26;143(4):326-336
pubmed: 33081531
Eur J Heart Fail. 2018 Aug;20(8):1230-1239
pubmed: 29431256
Eur J Heart Fail. 2021 Jul;23(7):1217-1225
pubmed: 34051124
N Engl J Med. 2019 Oct 24;381(17):1609-1620
pubmed: 31475794
Eur J Heart Fail. 2019 May;21(5):665-675
pubmed: 30895697
Eur J Heart Fail. 2019 Oct;21(10):1279-1287
pubmed: 31523904